Single Dose of Zilebesiran Linked to Reduction in Systolic BP
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 20, 2024 -- A single dose of subcutaneous zilebesiran is associated with a reduction in systolic blood pressure (SBP), according to a study published online Feb. 16 in the Journal of the American Medical Association.
George L. Bakris, M.D., from the University of Chicago in Illinois, and colleagues examined antihypertensive efficacy and safety of different zilebesiran dosing regimens in a phase 2 randomized trial. Participants were randomly assigned to one of four zilebesiran regimens (150, 300, or 600 mg once every six months or 300 mg once every three months) or placebo for six months. The full analysis set included 377 patients: 302 receiving zilebesiran and 75 receiving placebo.
The researchers found that the 24-hour mean ambulatory SBP changes were −7.3, −10.0, and −8.9 mm Hg with zilebesiran 150 mg once every six months, 300 mg once every three months or once every six months, and 600 mg every six months, respectively, compared with 6.8 mm Hg with placebo. In the change from baseline to month 3, the least-squares mean differences versus placebo were −14.1, −16.7, and −15.7 mm Hg for zilebesiran 150 mg every six months, 300 mg once every three months or six months, and 600 mg every six months, respectively. Over six months, 60.9 and 50.7 percent of patients receiving zilebesiran and placebo, respectively, had adverse events, and 3.6 and 6.7 percent, respectively, had serious adverse events.
"These data support further investigation of zilebesiran as a therapeutic strategy for patients with hypertension," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Alnylam Pharmaceuticals, which manufactures zilebesiran and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Social Determinants of Health Explain Disparities in Treatment-Resistant Hypertension
TUESDAY, May 21, 2024 -- Part of the association between race and incident apparent treatment‐resistant hypertension (aTRH) risk is mediated by social determinants of health, a...
Infertility Treatment Linked to Heart Disease Hospitalization
TUESDAY, May 21, 2024 -- Infertility treatment is associated with an increased risk for hospitalization due to heart disease, according to a study published in the May issue of...
Prehospital Reduction in BP Does Not Improve Stroke Outcomes
MONDAY, May 20, 2024 -- For patients with acute stroke, prehospital reduction in blood pressure does not affect functional outcomes, according to a study published online May 16...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.